GlassScriptPhysician profile
Michelle Duhe
NPI 1942646567
$7,355.41
in general payments reported to CMS, 2019-2025
43 companies · $19.85 in 2025
The $19.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $633 · 2021: $1,374 · 2022: $2,021 · 2023: $1,536 · 2024: $219 · 2025: $19.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $857.81 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $635.38 | 2019-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $620.33 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $587.19 | 2019-2023 | Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.31 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $409.67 | 2019-2023 | |
| Lilly USA, LLC | $408.21 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $311.32 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $287.72 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.92 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $261.21 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.64 | 2022-2023 | |
| Esperion Therapeutics, INC. | $184.14 | 2020-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $183.98 | 2019-2023 | Breztri |
| Abbott Laboratories | $173.18 | 2021-2025 | Freestyle Libre 3 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Duhe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.